Regulation of Fat-Stimulated Neurotensin Secretion in Healthy Subjects
Information source: University Hospital, Basel, Switzerland
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Fat perfusion to the small intestine (Dietary Supplement)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Basel, Switzerland Official(s) and/or principal investigator(s):
Juergen Drewe, MD, Principal Investigator, Affiliation: University Hospital, 4031 Basel, Switzerland
Christoph Beglinger, MD, Principal Investigator, Affiliation: Department of Research and Clinical Pharmacology, University Hospital, Basel Switzerland
Summary
Context: Cholecystokinin (CCK) and neurotensin are stimulated during meal intake by the
presence of fat in the small intestine. The sequence of events suggests that fat hydrolysis
is crucial for triggering the release.
Objectives: The aim of this study was therefore to investigate whether CCK mediated the
effect of intraduodenal (ID) fat on neurotensin secretion via CCK-1 receptors.
Clinical Details
Official title: Mechanistic Study (Physiology)
Study design: Basic Science, Randomized, Single Blind (Subject), Placebo Control, Crossover Assignment, Pharmacokinetics Study
Primary outcome: Neurotensin plasma concentrations
Detailed description:
Setting: Single center study; 34 male volunteers were studied in consecutive, randomized,
double blind, crossover studies.
Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects
receiving an ID fat infusion with or without 60 mg orlistat, an irreversible inhibitor of
gastrointestinal lipases, in comparison to vehicle. 2) 12 subjects receiving ID long chain
fatty acids (LCF), ID medium chain fatty acids (MCF) or ID vehicle. 3) 10 subjects receiving
ID LCF with and without the CCK-1 receptor antagonist dexloxiglumide (DEXLOX) or ID vehicle
plus IV saline (placebo). Hormone concentrations were measured by specific RIA systems.
Eligibility
Minimum age: 18 Years.
Maximum age: 35 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Healthy male subjects
Locations and Contacts
Clinical Research Center, University Hospital, Basel CH-4031, Switzerland
Additional Information
Related publications: Ferris CF, Carraway RE, Hammer RA, Leeman SE. Release and degradation of neurotensin during perfusion of rat small intestine with lipid. Regul Pept. 1985 Oct;12(2):101-11.
Starting date: January 2006
Ending date: March 2007
Last updated: October 9, 2007
|
